vs
MP Materials Corp.（MP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
MP Materials Corp.的季度营收约是REGENXBIO Inc.的1.7倍（$52.7M vs $30.3M），MP Materials Corp.净利率更高（17.9% vs -221.3%，领先239.2%），REGENXBIO Inc.同比增速更快（43.0% vs -13.6%），REGENXBIO Inc.自由现金流更多（$-52.8M vs $-109.3M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.0%）
MP Materials Corp.是总部位于美国的稀土材料生产商，拥有并运营加利福尼亚州芒廷帕斯矿，这是西半球唯一在产的稀土开采及加工设施，所产核心材料可广泛应用于电动汽车、风力发电机、国防工业等多个关键领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MP vs RGNX — 直观对比
营收规模更大
MP
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出56.6%
-13.6%
净利率更高
MP
高出239.2%
-221.3%
自由现金流更多
RGNX
多$56.5M
$-109.3M
两年增速更快
RGNX
近两年复合增速
4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $52.7M | $30.3M |
| 净利润 | $9.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -7.0% | -190.0% |
| 净利率 | 17.9% | -221.3% |
| 营收同比 | -13.6% | 43.0% |
| 净利润同比 | 142.2% | -31.2% |
| 每股收益（稀释后） | $0.07 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MPRGNX
| Q4 25 | $52.7M | $30.3M | ||
| Q3 25 | $53.6M | $29.7M | ||
| Q2 25 | $57.4M | $21.4M | ||
| Q1 25 | $60.8M | $89.0M | ||
| Q4 24 | $61.0M | $21.2M | ||
| Q3 24 | $62.9M | $24.2M | ||
| Q2 24 | $31.3M | $22.3M | ||
| Q1 24 | $48.7M | $15.6M |
净利润MPRGNX
| Q4 25 | $9.4M | $-67.1M | ||
| Q3 25 | $-41.8M | $-61.9M | ||
| Q2 25 | $-30.9M | $-70.9M | ||
| Q1 25 | $-22.6M | $6.1M | ||
| Q4 24 | $-22.3M | $-51.2M | ||
| Q3 24 | $-25.5M | $-59.6M | ||
| Q2 24 | $-34.1M | $-53.0M | ||
| Q1 24 | $16.5M | $-63.3M |
毛利率MPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率MPRGNX
| Q4 25 | -7.0% | -190.0% | ||
| Q3 25 | -125.2% | -176.3% | ||
| Q2 25 | -76.5% | -296.3% | ||
| Q1 25 | -57.2% | 13.6% | ||
| Q4 24 | -72.1% | -242.1% | ||
| Q3 24 | -62.8% | -256.6% | ||
| Q2 24 | -171.1% | -251.3% | ||
| Q1 24 | -66.6% | -408.8% |
净利率MPRGNX
| Q4 25 | 17.9% | -221.3% | ||
| Q3 25 | -78.0% | -208.3% | ||
| Q2 25 | -53.8% | -331.8% | ||
| Q1 25 | -37.2% | 6.8% | ||
| Q4 24 | -36.6% | -241.3% | ||
| Q3 24 | -40.5% | -246.3% | ||
| Q2 24 | -108.9% | -237.7% | ||
| Q1 24 | 33.9% | -405.4% |
每股收益（稀释后）MPRGNX
| Q4 25 | $0.07 | $-1.30 | ||
| Q3 25 | $-0.24 | $-1.20 | ||
| Q2 25 | $-0.19 | $-1.38 | ||
| Q1 25 | $-0.14 | $0.12 | ||
| Q4 24 | $-0.12 | $-0.99 | ||
| Q3 24 | $-0.16 | $-1.17 | ||
| Q2 24 | $-0.21 | $-1.05 | ||
| Q1 24 | $-0.08 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $230.1M |
| 总债务越低越好 | $998.7M | — |
| 股东权益账面价值 | $2.0B | $102.7M |
| 总资产 | $3.9B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.50× | — |
8季度趋势，按日历期对齐
现金及短期投资MPRGNX
| Q4 25 | $1.2B | $230.1M | ||
| Q3 25 | $1.1B | $274.2M | ||
| Q2 25 | $261.5M | $323.3M | ||
| Q1 25 | $198.3M | $267.9M | ||
| Q4 24 | $282.4M | $234.7M | ||
| Q3 24 | $284.4M | $255.5M | ||
| Q2 24 | $295.6M | $290.4M | ||
| Q1 24 | $296.5M | $338.7M |
总债务MPRGNX
| Q4 25 | $998.7M | — | ||
| Q3 25 | $997.3M | — | ||
| Q2 25 | $910.8M | — | ||
| Q1 25 | $909.8M | — | ||
| Q4 24 | $908.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MPRGNX
| Q4 25 | $2.0B | $102.7M | ||
| Q3 25 | $2.0B | $161.5M | ||
| Q2 25 | $1.0B | $213.7M | ||
| Q1 25 | $1.0B | $274.2M | ||
| Q4 24 | $1.1B | $259.7M | ||
| Q3 24 | $1.1B | $301.4M | ||
| Q2 24 | $1.1B | $348.3M | ||
| Q1 24 | $1.1B | $390.7M |
总资产MPRGNX
| Q4 25 | $3.9B | $453.0M | ||
| Q3 25 | $3.8B | $525.2M | ||
| Q2 25 | $2.3B | $581.0M | ||
| Q1 25 | $2.4B | $490.9M | ||
| Q4 24 | $2.3B | $466.0M | ||
| Q3 24 | $2.3B | $519.1M | ||
| Q2 24 | $2.4B | $569.4M | ||
| Q1 24 | $2.4B | $629.2M |
负债/权益比MPRGNX
| Q4 25 | 0.50× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.88× | — | ||
| Q4 24 | 0.86× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-46.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-109.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | -207.4% | -174.0% |
| 资本支出强度资本支出/营收 | 118.5% | 1.7% |
| 现金转化率经营现金流/净利润 | -4.97× | — |
| 过去12个月自由现金流最近4个季度 | $-328.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MPRGNX
| Q4 25 | $-46.9M | $-52.3M | ||
| Q3 25 | $-42.0M | $-56.0M | ||
| Q2 25 | $-3.7M | $-49.3M | ||
| Q1 25 | $-63.2M | $33.6M | ||
| Q4 24 | $30.5M | $-31.6M | ||
| Q3 24 | $-6.8M | $-40.5M | ||
| Q2 24 | $30.8M | $-45.5M | ||
| Q1 24 | $-41.1M | $-55.5M |
自由现金流MPRGNX
| Q4 25 | $-109.3M | $-52.8M | ||
| Q3 25 | $-92.5M | $-56.5M | ||
| Q2 25 | $-32.7M | $-49.7M | ||
| Q1 25 | $-93.7M | $32.6M | ||
| Q4 24 | $-11.2M | $-32.7M | ||
| Q3 24 | $-53.3M | $-40.9M | ||
| Q2 24 | $-15.6M | $-46.0M | ||
| Q1 24 | $-93.0M | $-56.0M |
自由现金流率MPRGNX
| Q4 25 | -207.4% | -174.0% | ||
| Q3 25 | -172.8% | -189.9% | ||
| Q2 25 | -56.9% | -232.8% | ||
| Q1 25 | -154.0% | 36.6% | ||
| Q4 24 | -18.3% | -154.2% | ||
| Q3 24 | -84.7% | -168.9% | ||
| Q2 24 | -50.1% | -206.2% | ||
| Q1 24 | -191.0% | -358.5% |
资本支出强度MPRGNX
| Q4 25 | 118.5% | 1.7% | ||
| Q3 25 | 94.3% | 1.7% | ||
| Q2 25 | 50.5% | 1.8% | ||
| Q1 25 | 50.1% | 1.2% | ||
| Q4 24 | 68.3% | 5.1% | ||
| Q3 24 | 73.8% | 1.3% | ||
| Q2 24 | 148.7% | 2.1% | ||
| Q1 24 | 106.5% | 3.6% |
现金转化率MPRGNX
| Q4 25 | -4.97× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -2.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MP
| Materials Segment | $35.6M | 68% |
| Other | $17.1M | 32% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
